Eledon Pharmaceuticals (ELDN) Current Assets (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Current Assets data on file, last reported at $113.6 million in Q1 2026.

• Quarterly Current Assets fell 11.07% year-over-year to $113.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $113.6 million (down 11.07% YoY) and the FY2025 annual result came in at $135.7 million, down 5.6% from the prior year.
• Current Assets eased to $113.6 million in Q1 2026, from $135.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $143.7 million in Q4 2024 to a low of $48.0 million in Q1 2024.
• A 5-year average of $86.2 million and a median of $79.3 million in 2022 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2023 — Current Assets slumped 38.35% — and 2025, when it surged 166.21%.
• Tracing ELDN's Current Assets over 5 years: stood at $59.5 million in 2022, then retreated by 5.69% to $56.1 million in 2023, then jumped by 156.07% to $143.7 million in 2024, then retreated by 5.6% to $135.7 million in 2025, then retreated by 16.3% to $113.6 million in 2026.
• The last three Current Assets figures came in at $113.6 million (Q1 2026), $135.7 million (Q4 2025), and $96.3 million (Q3 2025), per Business Quant data.